Renalytix (LON:RENX) Trading Down 17% – Should You Sell?

Renalytix Plc (LON:RENX) shares fell 17% during trading on Tuesday . The company traded as low as GBX 2.06 and last traded at GBX 2.06. 662,239 shares were traded during mid-day trading, a decline of 30% from the average session volume of 949,793 shares. The stock had previously closed at GBX 2.49.

Renalytix Trading Up 2.4%

The company has a current ratio of 2.43, a quick ratio of 2.42 and a debt-to-equity ratio of -599.34. The business has a 50 day simple moving average of GBX 4.06 and a two-hundred day simple moving average of GBX 6.21. The stock has a market cap of £9.40 million, a price-to-earnings ratio of -0.31 and a beta of 1.80.

Renalytix Company Profile

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).